Aligos Therapeutics Appoints Dr. Ramón Polo As SVP, Head Of Global Regulatory Affairs

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing therapies for liver and viral diseases, has announced the appointment of Dr. Ramón Polo, PharmD, PhD, MBA, as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. 

“I am excited to join the Aligos team as the company looks towards later-stage development. With my expertise leading global development and regulatory strategies at various pharma companies, I look forward to developing and implementing a comprehensive plan to aid in the continued development of ALG-000184,” stated Ramón Polo, MBA, PharmD, PhD, Senior Vice President, Head of Global Regulatory Affairs at Aligos. 

Dr. Polo brings extensive experience in regulatory leadership, having directed development teams, pharmacovigilance programs, and global regulatory strategies across multiple therapeutic areas. Most recently, he served as SVP, Head of Global Regulatory Affairs at Shionogi Inc., focusing on infectious diseases. Prior to that, he was VP, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs at Johnson & Johnson, where he was instrumental in addressing the challenges of developing and rolling out the company’s COVID-19 vaccine.

“I am thrilled to welcome Ramón to the leadership team at Aligos. As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón’s extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving global regulatory strategies will help guide Aligos at this pivotal time,” said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. 

Earlier in his career, Dr. Polo led regulatory strategies for influenza, RSV, and hepatitis C programs at Janssen Pharmaceuticals. He holds a PharmD, MSc, and PhD in Clinical Biochemistry from the Complutense University of Madrid, an MBA from the University of Navarra’s IESE Business School, and has completed executive training at Harvard Business School. His expertise strengthens Aligos’ global regulatory capabilities as the company advances its pipeline.